Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

A Digitally-Enabled System for Precision Assessment and Intervention of Disability Risk in Older Adults

NCT07508813 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-10-31
Last updated
2026-04-02

Condition(s) studied

Disability

Investigational drug(s) / intervention(s)

Risk Assessment of Disability and Precision Intervention

Risk Assessment of Disability and Precision Intervention: Implement a digital platform for elderly disability risk intervention to conduct comprehensive, multi-scenario intelligent assessments, dynamic monitoring, and targeted interventions for disability risks.

Study summary

1. Identify the primary risk factors for disability in older adults through multi-dimensional risk factor screening.
2. Develop a risk stratification model for disability in older adults by integrating outcome indicators and temporal characteristics, and construct an intelligent early warning model to enable automated assessment and monitoring of disability risk.
3. Establish key digital technologies for early warning and prevention of disability risk in older adults, and develop a whole-process digital intervention platform incorporating a decision support system for disability prevention management.
4. Create a digitally empowered hospital-community-household collaborative system for precise assessment and intervention of disability risk in older adults, achieving data-driven whole-process active disability management. The system will be demonstrated and evaluated in communities with diverse characteristics across urban, county, and rural settings.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Community-dwelling permanent residents aged ≥65 years; * Able to operate a smartphone independently or with assistance from a primary caregiver; * Clear consciousness with basic comprehension and communication abilities; * Voluntarily agree to participate in the study and provide informed consent. Exclusion Criteria: * Those who are unable to perform basic activities of daily living independently, or who have significant cognitive or communication impairments.

Primary outcome measure(s)

  • SPPB(SHORT PHYSICAL PERFORMANCE BATTERY PROTOCOL) — At baseline, 3 months after intervention, and 6 months after intervention
    the range of score is 0-12, and the higher scores mean a better outcome.

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital of Medical College of Zhejiang University Hangzhou Zhejiang Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07508813 on ClinicalTrials.gov ↗ ← All trials in China